Aliso Viejo, CA, July 11, 2025 (GLOBE NEWSWIRE) -- Galacxia, Inc., the developer of the Life Backup Plan app, is issuing a ...

This prestigious award recognizes a British Columbia-based biotechnology company demonstrating exceptional progress and achievement of key strategic milestones, attributes that reflect Variational ...

ISS and Glass Lewis are leading U.S. institutional voting advisory services that regularly publish analyses on public shareholder votes. Inmagene is a privately held, clinical stage biopharmaceutical ...

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the ...

Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion’s €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth ...

Classic steroids such as Dianabol, Trenbolone, Testosterone, and Deca Durabolin became mainstays in strength sports and ...

Milestone intends to use the net proceeds from the Offering, together with existing cash and cash equivalents, to fund the clinical development and commercial launch of etripamil in its lead ...

Completed ahead of schedule, the new facility is designed to anticipate growth as it more than doubles Tevogen’s previous ...

The Option Grant was made in reliance on the employment inducement exemption under the NYSE American’s Company Guide Section 711 (a) which requires public disclosure of inducement awards. Serina is ...

Reducing the number of shares that will be added to the Company’s outstanding shares from ~300,000 to between ~130,000-150,000 (subject to the share price upon warrant exercise). This amendment ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its Biologics License Application (BLA) ...

Fulcrum granted the new employee 130,000 options to purchase shares of the company’s common stock at an exercise price of $7.02 per share, the closing price per share of Fulcrum’s common stock as ...